Justification for conducting neurological clinical trials as part of patient care within private practice

被引:3
|
作者
Beran, R. G. [1 ,2 ,3 ,4 ]
Stepanova, D. [4 ]
Beran, M. E. [4 ]
机构
[1] Liverpool Hosp, Sydney, NSW, Australia
[2] Griffith Univ, Gold Coast, NSW, Australia
[3] Griffith Univ, Brisbane, NSW, Australia
[4] Strateg Hlth Evaluators, Sydney, NSW, Australia
关键词
CHRONIC DAILY HEADACHE; MULTIPLE-SCLEROSIS; DOUBLE-BLIND; ANTIEPILEPTIC DRUGS; PARTIAL SEIZURES; EPILEPSY; LEVETIRACETAM; GABAPENTIN; SAFETY; PROFILE;
D O I
10.1111/ijcp.12800
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this review was to assess the benefits and drawbacks of conducting neurological clinical trials and research in private practice for the patients, clinician, Practice Manager, sponsors/Clinical Research Organisations (CROs) and Clinical Trial Coordinator (CTC) to determine if this is justified for all involved. A combination of literature reviews, original research articles and books were selected from 2005 to 2015. Provided that the practice has sufficient number of active trials to prevent financial loss, support staff, adequate facilities and equipment and time, the benefits outweigh the drawbacks. Clinical trials provide patients with more thorough monitoring, re-imbursement of trial-related expenses and the opportunity to try an innovative treatment at no charge when other options have failed. For the clinician, clinical trials provide more information to ensure better care for their patients and improved treatment methods, technical experience and global recognition. Trials collect detailed and up-to-date information on the benefits and risks of drugs, improving society's confidence in clinical research and pharmaceuticals, allow trial sponsors to explore new scientific questions and accelerate innovation. For the CTC, industry-sponsored clinical trials allow potential entry for a career in clinical research giving CTCs the opportunity to become Clinical Research Associates (CRAs), Study Start-Up Managers or Drug Safety Associates.
引用
收藏
页码:365 / 371
页数:7
相关论文
共 50 条
  • [1] CONDUCTING CLINICAL TRIALS IN PRIVATE PRACTICE
    Beran, Roy G.
    Sathiyaseelan, Sandiya
    Hurley, Glynda K.
    Beran, Maureen E.
    [J]. MEDICINE AND LAW, 2018, 37 (01): : 27 - 36
  • [2] Conducting clinical trials in practice
    Muniz, M
    Cox, A
    [J]. IN PRACTICE, 2001, 23 (09) : 551 - 553
  • [3] Conduct of trials in private clinical practice
    Beran, RG
    Beran, ME
    [J]. EPILEPSIA, 2000, 41 (07) : 875 - 879
  • [4] Conducting a clinical practice audit - Fourteen steps to better patient care
    Godwin, M
    [J]. CANADIAN FAMILY PHYSICIAN, 2001, 47 : 2331 - 2333
  • [5] Clinical research trials in private practice.
    Erlichman, MS
    Delauter, SK
    Hayes, PN
    [J]. ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 1166 - 1166
  • [6] Clinical trials in Germany. The gastroenterologist in private practice as a partner in clinical trials
    Bokemeyer, B
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2004, 129 (14) : 764 - 766
  • [7] Do Clinical Trials Fit in a Private Medical Practice?
    Nahass, Ronald
    [J]. OPEN FORUM INFECTIOUS DISEASES, 2014, 1 (01):
  • [8] Conducting clinical trials in palliative care:: Roles and challenges
    Calder, K
    Tom, B
    Viganò, A
    [J]. JOURNAL OF PALLIATIVE CARE, 2000, 16 (03) : 74 - 74
  • [9] Financial concepts to conducting and managing clinical trials within budget
    Kovacevic, M
    [J]. DRUG INFORMATION JOURNAL, 2001, 35 (03): : 1031 - 1038
  • [10] Financial Concepts to Conducting and Managing Clinical Trials Within Budget
    Milan Kovacevic
    Olalekan E. Odeleye
    William K. Sietsema
    Kevin M. Schwarz
    Carl R. Torchio
    [J]. Drug information journal : DIJ / Drug Information Association, 2001, 35 (3): : 1031 - 1038